Clinical Trial Update: Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating camrelizumab in combination with docetaxel and cisplatin for recurrent or metastatic oral squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Camrelizumab (camrelizumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Oral Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN